| Strengthening the Bio-Tech Landscape Through Clinical Approvals and Global Commercialization Support
JNPMEDI (CEO, KwunHo Jeong) announced on the 12th that it has been signed Memorandum of Understanding (MOU) with the Foundation for Medical Innovation (FMI) to collaborate on clinical approvals and investment support for pharmaceutical and medical device companies. This agreement aims to facilitate the smooth growth of pharmaceutical and medical device companies during clinical development and commercialization stages, while enhancing their competitiveness in the global market.
Under the term of this agreement, two organizations will work together in several key areas including, △ regulatory approvals and clinical trials for pharmaceuticals and medical devices, △ support for clinical development and commercialization, and △ joint investment reviews and strategic partnerships with FMI’s affiliated companies. In particular, the FMI will actively facilitate collaboration between its partner companies and JNPMEDI. Meanwhile, JNPMEDI plans to contribute to the broader domestic bio-ecosystem through regulatory consulting, clinical trial management, and investment reviews.
JNPMEDI CEO, KwunHo Jeong stated that “This agreement is a major milestone in establishing a platform for domestic biotech and medical device companies to expand into the global market. Through collaboration with the FMI, we aim to achieve innovative outcomes by establishing joint investment models in addition to regulatory approvals and commercialization.”
A representative from the FMI remarked, “This agreement will significantly enhance key partnerships in the biotech industry and support our partner companies in achieving success throughout clinical and commercialization processes. By leveraging JNPMEDI’s expertise, we will build collaborative models that enhance global competitiveness.”
Together, the two organizations are committed to strengthening the global competitiveness of pharmaceutical and medical device companies while driving innovation in regulatory and commercialization practices.
| Strengthening the Bio-Tech Landscape Through Clinical Approvals and Global Commercialization Support
JNPMEDI (CEO, KwunHo Jeong) announced on the 12th that it has been signed Memorandum of Understanding (MOU) with the Foundation for Medical Innovation (FMI) to collaborate on clinical approvals and investment support for pharmaceutical and medical device companies. This agreement aims to facilitate the smooth growth of pharmaceutical and medical device companies during clinical development and commercialization stages, while enhancing their competitiveness in the global market.
Under the term of this agreement, two organizations will work together in several key areas including, △ regulatory approvals and clinical trials for pharmaceuticals and medical devices, △ support for clinical development and commercialization, and △ joint investment reviews and strategic partnerships with FMI’s affiliated companies. In particular, the FMI will actively facilitate collaboration between its partner companies and JNPMEDI. Meanwhile, JNPMEDI plans to contribute to the broader domestic bio-ecosystem through regulatory consulting, clinical trial management, and investment reviews.
JNPMEDI CEO, KwunHo Jeong stated that “This agreement is a major milestone in establishing a platform for domestic biotech and medical device companies to expand into the global market. Through collaboration with the FMI, we aim to achieve innovative outcomes by establishing joint investment models in addition to regulatory approvals and commercialization.”
A representative from the FMI remarked, “This agreement will significantly enhance key partnerships in the biotech industry and support our partner companies in achieving success throughout clinical and commercialization processes. By leveraging JNPMEDI’s expertise, we will build collaborative models that enhance global competitiveness.”
Together, the two organizations are committed to strengthening the global competitiveness of pharmaceutical and medical device companies while driving innovation in regulatory and commercialization practices.